Stock Analiz

Sonoma Pharmaceuticals, Inc. SNOA

Medical/Dental Instruments · IPO 2007 · data as of November 13, 2026

$1.09Market cap $6M
Open the interactive analysis →

Sonoma Pharmaceuticals, Inc. (SNOA) is a healthcare company listed in the US with a market value of about $6M. In the twelve months to September 30, 2026 it had revenue of $23M and net income of -$2M, a net margin of -7.6%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is track record (0/5).

Key numbers: 5-year revenue growth of 1% a year, a 5-year average ROIC of -60%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 77% above the current price.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals is listed in the US and classified in medical/dental instruments, IPO year 2007. Revenue went from $14M in 2015 to $20M in 2026, growth of about 3.2% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 891% over three years (dilution for shareholders). It spends 12% of revenue on research and development.

Score: 1.4 / 5

Value1/5
Future growth4/5
Track record0/5
Financial health1/5
Shareholder returns1/5

Checks passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.2
P/B0.8
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-50.5%
Shareholder yield0.0%
Intrinsic value vs. price+77%

Growth and quality

Revenue growth (1 yr)36.7%
Revenue growth (5 yrs, per year)0.9%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-31.5%
ROIC (5-yr avg.)-59.5%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2026202520242023202220212020201920182017
Revenue$23M$20M$14M$13M$13M$13M$19M$18M$19M$17M$13M
Net income-$2M-$3M-$3M-$5M-$5M-$5M-$4M-$3M-$12M-$14M$9M
Free cash flow-$3M-$4M-$168000-$2M-$6M-$4M-$4M-$5M-$12M-$13M-$9M
EPS (diluted)$-0.91$-1.89$-2.79$-10.63$-30.37$-0.04$-0.04$-0.04$-0.26$-0.57$0.40
Net margin-7.6%-16.3%-24.2%-38.0%-38.8%-40.3%-21.2%-18.4%-62.2%-86.0%72.3%
ROIC—-58.1%-62.2%-67.0%-51.4%-58.9%-33.9%-82.2%-92.6%-71.9%-40.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Sonoma Pharmaceuticals stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 77% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Sonoma Pharmaceuticals pay a dividend?

Not currently.

Is Sonoma Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. Sonoma Pharmaceuticals scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.